Interferon Alpha (IFNA) - Drugs in Development, 2021
Summary Interferon Alpha (IFNA) - Drugs in Development, 2021 provides in depth analysis on Interferon Alpha (IFNA) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Additionally, the report provides an overview of key players involved in Interferon Alpha (IFNA) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products across relevant therapy areas under development targeting Interferon Alpha (IFNA).
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: * This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase. * Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope - The report provides a snapshot of the Global therapeutic landscape for Interferon Alpha (IFNA). - The report reviews Interferon Alpha (IFNA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. - The report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive Mechanism of Action (MoA), Research and Development (R&D) brief, Licensing and Collaboration details & Other Developmental Activities. - The report reviews key players involved in Interferon Alpha (IFNA) targeted therapeutics and enlists all their major and minor projects. - The report assesses Interferon Alpha (IFNA) targeted therapeutics based on Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. - The report summarizes all the dormant and discontinued pipeline projects. - The report reviews latest news and deals related to Interferon Alpha (IFNA) targeted therapeutics.
Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective Research and Development (R&D) strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Identify and understand the targeted therapy areas and indications for Interferon Alpha (IFNA). Identify the use of drugs for target identification and drug repurposing. - Identify potential new clients or partners in the target demographic. - Develop strategic initiatives by understanding the focus areas of leading companies. - Plan Mergers and Acquisitions (M&A) effectively by identifying key players and it’s most promising pipeline therapeutics. - Devise corrective measures for pipeline projects by understanding Interferon Alpha (IFNA) development landscape. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Our reports have been used by over 10K customers, including:
Interferon Alpha/Beta Receptor 2 (Interferon Alpha Binding Protein or Type I Interferon Receptor 2 or IFNAR2) - Drugs in Development, 2021 Summary Interferon Alpha/Beta Receptor 2 (Interferon Alpha Binding Protein or Type I Interferon Receptor 2 or IFNAR2) - Drugs in Development, 2021 provides in...
Interferon Alpha/Beta Receptor 1 (Cytokine Receptor Class II Member 1 or Cytokine Receptor Family 2 Member 1 or Type I Interferon Receptor 1 or IFNAR1) - Drugs in Development, 2021 Summary Interferon Alpha/Beta Receptor 1 (Cytokine Receptor Class II Member 1 or Cytokine Receptor Family 2 Member 1...
175 pages •
By The Business Research Company
• Jun 2021
Major players in the enzymes market are Sanofi, AbbVie Inc., Alexion Pharmaceuticals Inc, Horizon Pharma, Allergan plc, Pfizer Inc., Vivus, Digestive Care, Leadiant Biosciences, and Roche Holdings AG The global enzymes market is expected to grow from $7.81 billion in 2020 to $8.9 billion in 2021 at a compound annual growth rate (CAGR)...
The global single-use assemblies market is projected to reach USD 6.3 billion by 2026 from USD 2.2 billion in 2021, at a CAGR of 23.3% during the forecast period. The growth of the single-use assemblies market can primarily be attributed to the major advantages of single-use technologies as compared to traditional stainless-steel assemblies,...
The Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2021: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right...
“Axial spondyloarthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route...
The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2021 report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets. The report provides a detailed understanding and analysis of how and why companies enter business, product,...
176 pages •
By Global Industry Analysts
• Apr 2021
- Global Carglumic Acid Market to Reach $167.4 Million by 2027
- Amid the COVID-19 crisis, the global market for Carglumic Acid estimated at US$109.3 Million in the year 2020, is projected to reach a revised size of US$167.4 Million by 2027, growing at aCAGR of 6.3% over the period 2020-2027. Tablet, for...
133 pages •
By Global Industry Analysts
• Apr 2021
- Global Biological Drugs Market to Reach $427.4 Billion by 2027
- Amid the COVID-19 crisis, the global market for Biological Drugs estimated at US$234.3 Billion in the year 2020, is projected to reach a revised size of US$427.4 Billion by 2027, growing at a CAGR of 9% over the analysis period 2020-2027....
781 pages •
By Global Industry Analysts
• Apr 2021
- Global Biopharmaceuticals Market to Reach $535 Billion by 2027
- Amid the COVID-19 crisis, the global market for Biopharmaceuticals estimated at US$234.5 Billion in the year 2020, is projected to reach a revised size of US$535 Billion by 2027, growing at a CAGR of 12.5% over the analysis period 2020-2027....
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.